Related Experiment Video
Updated: Apr 29, 2026
05:35
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
1.9K
Medical and pharmacy coverage decision making at the population level
1Center for Medical Technology Policy, 401 E. Pratt, Ste. 631, Baltimore, MD 21202. penny.mohr@cmtpnet.org.
Journal of Managed Care & Specialty Pharmacy
|May 27, 2014
Summary
Medicare coverage decisions impact patient access to care. Evidence on treatment effect variations informed Medicare
Area of Science:
- Health Policy
- Medical Economics
- Clinical Decision Making
Background:
- Medicare is a major US health insurer, influencing patient access to treatments.
- Coverage decisions significantly affect healthcare utilization and outcomes.
- Comparative effectiveness research (CER) is increasingly available.
Purpose of the Study:
- To describe Medicare's use of heterogeneity of treatment effects (HTE) evidence for coverage decisions.
- To examine the role of HTE in policy-making for implantable cardiac defibrillators.
- To discuss the implications of CER for healthcare coverage and clinical practice.
Main Methods:
- Analysis of Medicare's coverage policy for implantable cardiac defibrillators.
- Review of evidence on heterogeneity of treatment effects in clinical research.
- Discussion of the interplay between population-based and patient-centered decision-making.
Main Results:
- Medicare utilized HTE evidence to guide population-based coverage for implantable cardiac defibrillators.
- CER provides valuable data for nuanced policy and clinical choices.
- Balancing population needs with individual patient preferences is crucial.
Conclusions:
- Medicare's approach demonstrates the practical application of HTE in health policy.
- Expanded CER can support more informed and personalized healthcare decisions.
- Integrating diverse evidence enhances the precision of coverage policies.
More Related Videos
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
993
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
993
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:03Drug Control Governance: Regulatory Bodies and Their Impact
702
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
702
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
544
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
544
01:26Pharmaceutical Poisoning: Potential Scenarios
116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116